STRIBILD
Peakelvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate
NDAORALTABLET
Approved
Aug 2012
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
14
Mechanism of Action
Cytochrome P450 3A Inhibitors
Pharmacologic Class:
Cytochrome P450 3A Inhibitor
Clinical Trials (5)
Atripla to Stribild Switch Study to Evaluate Sleep Disturbances
Started Feb 2015
21 enrolled
HIVAIDSSleep Disorders
Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults
Started Dec 2014
72 enrolled
HIV-1 Infection
STRIBILD in Non-Nucleoside Resistant Patients (SINNR STUDY)
Started Nov 2014
30 enrolled
HIVIllicit Drug User
Sleep and Cognition After Atripla to Stribild Switch
Started Sep 2014
30 enrolled
HIV
An Open Label Trial of Stribild for Antiretroviral (ARV)-naïve HIV-2 Infected Adults in Dakar, Senegal
Started Sep 2014
30 enrolled
HIV-2 Infection
Loss of Exclusivity
LOE Date
Apr 6, 2033
86 months away
Patent Expiry
Apr 6, 2033
Patent Records (5)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 7176220 | Aug 27, 2026 | SubstanceProduct | U-257 |
| 7635704 | Oct 26, 2026 | SubstanceProduct | U-257 |
| 8981103 | Oct 26, 2026 | SubstanceProduct | — |
| 7176220*PED | Feb 27, 2027 | — | |
| 8981103*PED | Apr 26, 2027 | — |